$ALAB

Astera Labs (ALAB) Q2 2026 Earnings Call Transcript

Astera Labs (NASDAQ:ALAB) reported Q2 2026 revenue of $392.4M, up 27% sequentially and 104% year over year, with non-GAAP gross margin of 73.7% and non-GAAP diluted EPS of $0.80. Q3 guidance calls for revenue of $540M to $560M and EPS of $1.16 to $1.21, driven by the Scorpio X-Series ramp and PCIe 6.0 adoption.

Original reporting
Published Aug 11, 2026, 11:43 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Astera Labs (ALAB) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ALABBullishMed
01

Why it matters

Traders can update near-term models using the provided Q3 revenue and non-GAAP EPS guidance, and assess margin trajectory risk from product mix shifts. Longer-dated catalysts (2027 NPO, 2028 CPO switch roadmap, 2027 Leo CXL volume production) inform longer-horizon positioning but are less actionable for immediate trading.

02

Market read

Q2 execution and explicit Q3 guidance (revenue and non-GAAP EPS) are the primary tradable inputs, with margin mix risk as the key offset.

03

What to watch

Guidance is heavily dependent on Scorpio X-Series scaling in the second half of 2026 and multiple 2027-2028 volume production milestones; any ramp delays could pressure forward estimates despite strong Q2 prints.

Relevance 8/10Novelty 7/10Timing: post-call, ahead of Q3 expectations

Background

This is a transcript-style summary of Astera Labs’ Q2 2026 earnings call, including management takeaways, guidance, and forward-looking production timelines.

Company-level read

Ticker impact

$ALABBullishMedium confidence
Context

Astera Labs reported Q2 revenue of $392.4M and guided Q3 revenue to $540M-$560M, driven by Scorpio X-Series volume ramp.

Expected impact

Likely positive bias for the next few sessions as traders price in Q3 revenue/EPS and operating leverage, tempered by the stated gross-margin mix risk.

Evidence & confidence

The call provides specific Q2 results plus explicit Q3 revenue and non-GAAP EPS guidance, and management links them to identifiable product ramps (Scorpio X-Series) and mix (PCIe 6.0, silicon vs module). It also flags a potential gross-margin decline from current levels as mix shifts, which can cap upside.

Market effects

Reinforces demand momentum for high-speed interconnect and PCIe 6.0/optical connectivity roadmaps, supporting sentiment for data center connectivity supply chain.

China revenue mix expected to stay in single digits, implying growth is more dependent on other regions and hyperscaler capex cycles.

Hyperscaler design wins and CXL/optical roadmap milestones can influence broader AI infrastructure capex expectations.

Counterpoint

The gross margin is expected to trend toward a 70% long-term target, and management explicitly warns quarterly mix can swing margins, so upside may be less durable than revenue growth implies.

Key entities

  • Astera Labs, Inc.

    NASDAQ-listed semiconductor connectivity supplier reporting Q2 results and issuing Q3 guidance tied to PCIe 6.0 and Scorpio X-Series ramps.

  • Jitendra Mohan

    CEO and co-founder who highlighted PCIe 6.0 adoption and CXL ecosystem momentum.

  • Desmond Lynch

    CFO who discussed gross margin trajectory and mix-driven variability.

Related articles

$ALABMed

ALAB Benefits From PCIe Demand: Can It Stay Ahead of Its Competitors?

Astera Labs (ALAB) reported record Q2 2026 revenue of $392.4M, up 104% year over year, with PCIe 6 products at over 50% of revenue. The company said Scorpio X-Series will be its largest product family by Q3 2026. It expects Q3 revenue of $540M-$560M. The article also cites competition from Marvell (MRVL) and Credo (CRDO).

$ALABHighAI 9/10

Alamar Biosciences Shares Rise 18% After Second-Quarter Revenue Jumps 82% Year-Over-Year

Alamar Biosciences shares rose about 18% after the company reported Q2 2026 revenue of $29.4 million, up 82% year over year, and provided first full-year 2026 revenue guidance of $116 million to $120 million. The stock closed at $32.91. Alamar also launched new NULISAseq panels and set targets to exceed 100 instrument systems and $400,000+ annual pull-through per instrument.

$ALABMed

Astera Labs Beat And Guided Higher, Then Fell Because The Rally Came First

Astera Labs (ALAB) reported record fiscal Q2 2026 results, with revenue of $392.4M up 104% year over year, and issued fiscal Q3 2026 guidance of $540M to $560M, above expectations. The stock later fell about 12% after four prior up sessions. The article attributes the shift to product mix, with PCIe 6 and Scorpio switch family ramping, and a non-GAAP gross margin guide down to about 72% from 74%.